If you have brittle nails, swollen hands or unusually pale fingertips it may be more than just a damper to your manicure. It ...

THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.

Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the biopharmaceutical company. Read more here.

ICFO has now used the LUCA platform to characterize the thyroid tissue with simultaneous anatomical measurements, the first ...

The company’s chronic thyroid eye disease treatment, veligrotug, was able to reduce eye bulge by 56% compared with placebo.

In Iowa, the powerful Farm Bureau and other ag industry groups oppose regulations that limit fertilizer application or ...

Veligrotug is an investigational monoclonal antibody that inhibits the activity of insulin-like growth factor-1 receptor.

Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the ...

The company’s stock could continue to see upward momentum, especially if upcoming trials, such as those for VRDN-003, yield positive results. The potential approval of veligrotug could lead to a ...

Viridian Therapeutics, Inc. has recently announced positive topline results from the phase 3 Thrive-2 clinical trial of ...

Viridian (VRDN) shares shot up 25% after the company reported positive results from a Phase 3 study of veligrotug in the ...

Novo Nordisk is investing $1.2 billion in a rare disease drugs facility in Denmark, weight-loss drugs surge American ...